Ultragenyx Pharmaceutical (RARE) has completed the rolling submission of its U.S. marketing application for its gene therapy candidate DTX401 for a rare disorder called Glycogen Storage Disease Type Ia.
Having received multiple FDA designations, including the fast-track designation for DTX401, the company